CN109497376A - A kind of ERAS energy drink and preparation method thereof - Google Patents
A kind of ERAS energy drink and preparation method thereof Download PDFInfo
- Publication number
- CN109497376A CN109497376A CN201811245988.2A CN201811245988A CN109497376A CN 109497376 A CN109497376 A CN 109497376A CN 201811245988 A CN201811245988 A CN 201811245988A CN 109497376 A CN109497376 A CN 109497376A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- eras
- energy
- energy drink
- maltodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015897 energy drink Nutrition 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 19
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 67
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 60
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 42
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 33
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 33
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 33
- 239000001103 potassium chloride Substances 0.000 claims abstract description 33
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 33
- 239000001509 sodium citrate Substances 0.000 claims abstract description 29
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 29
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 22
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 22
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 22
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 22
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 21
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 21
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000011090 malic acid Nutrition 0.000 claims abstract description 21
- 239000001630 malic acid Substances 0.000 claims abstract description 21
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003495 thiamine Drugs 0.000 claims abstract description 21
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 21
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 21
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 21
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 21
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 21
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 21
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 19
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 19
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 19
- 235000015165 citric acid Nutrition 0.000 claims abstract description 3
- -1 oligofructose Substances 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 3
- 235000013361 beverage Nutrition 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 240000008397 Ganoderma lucidum Species 0.000 claims description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 3
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 abstract description 26
- 230000006641 stabilisation Effects 0.000 abstract description 3
- 238000011105 stabilization Methods 0.000 abstract description 3
- 206010049976 Impatience Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 19
- 239000011591 potassium Substances 0.000 description 16
- 229910052700 potassium Inorganic materials 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 230000035622 drinking Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 235000003642 hunger Nutrition 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000037351 starvation Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- 206010063429 Aase syndrome Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to special medicine formula food manufacture fields; a kind of ERAS energy drink is specifically disclosed, is made of following raw material: maltodextrin, oligofructose, vitamin B1, vitamin B6, vitamin B12, potassium chloride, zinc gluconate, sodium citrate, citric acid, malic acid, taurine, water.Compared with the prior art, the present invention provides a kind of ERAS energy drinks, enough nutrition and energy can be provided for human body, Energy intaking can be provided for operation consent patient, alleviate thirsty impatience, and the incidence of preoperative hypopotassaemia and the severity of hypopotassaemia can be reduced.The energy drink of the mentioned offer of the present invention simultaneously is stablized, and viscosity stabilization is suitable for that mouthfeel is good.
Description
Technical field
The present invention relates to special medicine formula food manufacture fields, and in particular to a kind of ERAS energy drink and its preparation
Method.
Background technique
Rehabilitation surgery (Enhanced Recovery After Surgery, ERAS) this concept is accelerated to start in recent years
As clinical hot spot.What surgery branch, Chinese Medical Association and anesthesiology branch, Chinese Medical Association formulated " accelerates rehabilitation surgery
Chinese Consensus of experts and path management guide " in point out, accelerate rehabilitation surgery refer to make patient's quick recovery, in peri-operation period
Effective optimization processing measure is confirmed through evidence-based medical using a series of, is answered with mitigating patients ' psychological and physiological wound
Swash reaction, to reduce complication, reduce risk, while reducing patient's time cost and economic cost, improving patient's Perinatal Therapy
Phase quality of life.
Currently, most domestic surgical operation requires patient to shift to an earlier date fasting in 8 hours before proceeding, prohibit within 4 hours in advance
Water.Research has shown that preoperative long-time fasting makes during operation and postoperative Systemic stress response enhances, and carbohydrate metabolism disturbance, machine occurs
The increase of body catabolism, decomposition of glycogen acceleration, negative nitrogen balance, sugar tolerance decline etc. restore unfavorable to patient.There is document report
The hypopotassaemia incidence about 20% in all inpatient groups, and inventor has found in early-stage study, preoperative row machine
Tool INTESTINAL CLEANSING and tradition prohibit the patient of drink and fasting, and can lead to up to 70.37% patient, preoperative there are hypopotassaemias.
In perioperative, hypopotassaemia, which can lead to, there are a variety of arrhythmia cordis in patient's art, severe person can even occur aase's syndrome and
Situations such as respiratory paralysis and threaten patient vitals.Meanwhile hypopotassaemia can also cause postoperative abdominal distention, enteroparalysis, influence enteron aisle function
The recovery of energy, the hospital stays for extending patient and the hospitalization cost for increasing patient, or even influence the prognosis of patient.It can be seen that
The preoperative long-time nothing by mouth of patient does not simultaneously meet acceleration rehabilitation surgery theory.
For preoperative nothing by mouth, the current country generallys use the mode of 5% glucose saline intravenous injection
Supplement energy, however this mode absorbs too fast, moisture can be quickly converted to urine, increase kidney burden.There are also studies have shown that
Preoperative 12h, which drinks 800ml or preoperative 2~3h and drinks the beverage of 400ml carbohydrate containing, can reduce anxiety, starvation, thirsty
Feel, reduce catabolism effect caused by fasting and Fundamental Operations, moreover it is possible to effectively improve insulin level, reduce it is postoperative
Insulin resistance maintains glycogen deposit, reduces muscle breakdown, improves muscular strength, maintenance immune function, however the program can not
The incidence of preoperative hypopotassaemia is reduced, perioperative still has certain risk.
Summary of the invention
To overcome existing technological deficiency, it can reduce preoperative hypopotassaemia incidence the present invention provides one kind and subtract
The energy drink and preparation method thereof of light low potassium severity.
To achieve the purpose of the present invention, it is achieved using following technical scheme:
A kind of ERAS energy drink, is made of following raw material: maltodextrin, oligofructose, vitamin B1, vitamin B6,
Vitamin B12, potassium chloride, zinc gluconate, sodium citrate, citric acid, malic acid, taurine, water.
As a preferred solution, in above-mentioned ERAS energy drink, the weight of potassium chloride is in every 100ml beverage
0.2~0.7g.Wherein, potassium chloride additive amount is too low, then is difficult to reach and is greatly reduced preoperative hypopotassaemia incidence, mitigates and suffers from
The effect of the low potassium degree of person；And potassium chloride adding too much is then easy to influence the mouthfeel of energy drink.
As a preferred solution, above-mentioned ERAS energy drink, wherein every 100ml beverage is by following each of weight
Material composition:
12~14g of maltodextrin, 3~50g of oligofructose, 0.2~0.3mg of vitamin B1, vitamin B6 0.1~
0.2mg, 0.1~0.2ug of vitamin B12,0.3~0.6g of potassium chloride, 10~12ug of zinc gluconate, sodium citrate 0.1~
0.4g, 0.1~0.4g of citric acid, 1~30mg of malic acid, 20~50mg of taurine, remaining is water.
In technical solution of the present invention, effect is summarized as follows the effect of each component:
Carbohydrate: carbohydrate includes maltodextrin (M200), oligofructose in the present invention.It is well known that sugared
Class carbohydrate is that all living things body sustains life the main source of energy needed for activity, can obviously eliminate drinking person
Hunger.Meanwhile the present invention, using oligofructose, relative to monosaccharide, oligofructose can be absorbed by the body, and absorb not
It is too short as too fastly, can be avoided energy drink energy supply time in surgical procedure, occur human body power supply in operation and is in an emergency, or
Product after absorption of human body causes related organ burden is excessive to lead to operative failure.
Vitamin: vitamin B1, B6, B12 in formula of the invention can promote carbohydrate to exist to a certain extent
Intracorporal metabolic adsorption, can also act synergistically improves drinking person mental status, maintains nervous system, nerve fiber, muscle, the heart
It is dirty etc. movable normal, alleviate the unhealthy emotion of drinking person.
Taurine: mainly serve antifatigue.
Zinc gluconate: containing suitable zinc gluconate in the present invention, mainly plays a part of to improve the sense of taste.
Food additives: food additives include sodium citrate, citric acid, malic acid, mainly adjusting mouth in the present invention
Taste and pH value.Sodium citrate also forms the complexing of stable good water solubility with calcium, the ferro element in maltodextrin in the present invention
Object.The complex compound also increases the viscosity of beverage, while sodium citrate itself also plays the role of thickening, keeps beverage of the present invention viscous
Degree is stably maintained at 1.3~1.8mpas (25 DEG C).Energy drink viscosity provided by the present invention is higher, there is similar liquid food
Feel there is apparent feed sense when can drinking person be drunk, to enhance drinking person to the confidence of its effect, Jin Erjin
One step promotes the effect of beverage of the present invention.
Potassium chloride: it can effectively reduce preoperative hypopotassaemia incidence and mitigate low potassium severity, and accelerate postoperative stomach and intestine
Functional rehabilitation facilitates the rehabilitation of patient.Oral benefit clinically is mostly used for light-duty hypopotassaemia or preventive usage at present
The mode of potassium, however directly oral 10% Klorvess Liquid, to the irritating effect of alimentary canal mucous membrane, patient may occur in which evil after taking
The adverse reactions such as the heart, vomiting, epigastric discomfort even result in peptic ulcer and bleeding.Relative to directly clinically direct mouth
The mode of potassium chloride injection is taken, energy drink provided by the present invention is easy, quickly and safely reaches and mends potassium effect, and not
It will appear and patient is allowed to generate the adverse reactions such as Nausea and vomiting, abdominal distension, abdominal pain.In addition, potassium chloride used in this research is more sticked on
Clinically widely used potassium chloride injection is closed, for the patient of severe hypopotassaemia, can be needed according to actual clinical additional
Potassium chloride injection is added, does not influence the stability of mixed liquor, can directly drink for patient to correct hypopotassaemia.
ERAS energy drink appearance stablity provided by the present invention places clear, colorless for a long time, and viscosity stabilization is suitable,
Make drinking person smooth mouth feel when drinking.The present invention contains a large amount of carbohydrate and suitable vitamin, and the two can be famine
Hungry crowd quickly provides energy, is especially suitable for providing energy for preoperative patient, while vitamin can also improve drinking person essence
Refreshing situation, maintenance nervous system, nerve fiber, muscle, heart etc. are movable normal, alleviate the unhealthy emotion of drinking person, together
When, the incidence of preoperative hypopotassaemia and the severity of hypopotassaemia can be also reduced, and can promote postoperative gastrointestinal tract exhaust row
Just the recovery of function, promote patient early out-of-bed activity, be conducive to the acceleration rehabilitation of patient, be one kind be particularly suitable for plus
The energy drink of the energy supplement of operation consent patient under fast rehabilitation surgery theory guidance.
It is further preferred that the weight of potassium chloride is 0.4~0.5g in every 100ml beverage.
The pH value of energy drink of the present invention controls between 4.0~5.0, is guaranteeing to generate smaller shadow to gastrointestinal tract pH value
Possess good mouthfeel while sound, is easy to be received by patient.
Preferably, the maltodextrin is M200 type.
Preferably, the taurine is substituted by one or more of ginseng, Schisandra chinensis, rhizoma polygonati, ganoderma lucidum, Morinda officinalis.
Energy drink provided by the present invention is mainly used in preoperative supplement energy while preventing preoperative potassium low with perioperative
The generation of mass formed by blood stasis is particularly suitable for the preoperative patient for needing row mechanicalness INTESTINAL CLEANSING and tradition taboo drink and fasting.
A kind of preparation method of above-mentioned ERAS energy drink, which comprises the steps of:
(1) maltodextrin and a certain amount of water are weighed, is completely dissolved maltodextrin under the action of ultrasound after mixing,
Obtain maltodextrin aqueous solution；
(2) sodium citrate and a certain amount of water are weighed, 40~50 DEG C of stirrings is heated to being completely dissolved, is cooled to room temperature
Obtain sodium citrate aqueous solution；
(3) the maltodextrin aqueous solution made from step (1) is poured into material-compound tank A, lower addition is then stirred at room temperature
Sodium citrate aqueous solution made from step (2) obtains solution A；
(4) oligofructose, vitamin B1, vitamin B6, vitamin B12, zinc gluconate, taurine, lemon are weighed
Material-compound tank B is added in acid, malic acid, potassium chloride and a certain amount of water, is then heated to 40~50 DEG C of stirrings to after being completely dissolved,
It is cooled to room temperature, obtains solution B；
(5) water constant volume is used after mixing solution A and B, then sterilized, cooled down, is filling, packaging.
Compared with the prior art, the present invention provides a kind of ERAS energy drinks, and enough nutrition can be provided for human body
And energy, Energy intaking can be provided for operation consent patient, alleviate thirsty impatience, and the hair of preoperative hypopotassaemia can be reduced
The severity of raw rate and hypopotassaemia.The energy drink of the mentioned offer of the present invention simultaneously is stablized, and viscosity stabilization is suitable for mouthfeel
It is good.
Specific embodiment
To make the object, technical solutions and advantages of the present invention clearer, embodiment of the present invention is made below further
It explains in detail.
Embodiment 1
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 12g, oligofructose 45g, vitamin B1 0.2mg, vitamin B6 0.1mg, vitamin B12
0.1ug, potassium chloride 0.3g, zinc gluconate 10ug, sodium citrate 0.1g, 0.1 g of citric acid, malic acid 1mg, taurine
20mg, remaining is water.
The preparation method of above-mentioned ERAS energy drink, includes the following steps:
(1) maltodextrin and a certain amount of water are weighed, is made under the action of frequency is the ultrasound of 20~80KHz after mixing
Maltodextrin is completely dissolved, and obtains maltodextrin aqueous solution, wherein maltodextrin: water=1g: 2~4ml；
(2) sodium citrate and a certain amount of water are weighed, 40~50 DEG C of stirrings is heated to being completely dissolved, is cooled to room temperature
Sodium citrate aqueous solution is obtained, wherein sodium citrate: water=1g: 8~12ml；
(3) the maltodextrin aqueous solution made from step (1) is poured into material-compound tank A, lower addition is then stirred at room temperature
Sodium citrate aqueous solution made from step (2) obtains solution A；
(4) oligofructose, vitamin B1, vitamin B6, vitamin B12, zinc gluconate, taurine, lemon are weighed
Acid, malic acid, potassium chloride are added material-compound tank B, and a certain amount of water are added, and are then heated to 40~50 DEG C and stir to completely molten
Xie Hou is cooled to room temperature, and obtains solution B, wherein oligofructose, vitamin B1, vitamin B6, vitamin B12, potassium chloride, Portugal
The total weight of grape saccharic acid zinc, taurine, citric acid, malic acid: water=1g: 8~12ml；
(5) water constant volume is used after mixing solution A and B, then sterilized, cooled down, is filling, packaging.
Embodiment 2
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 5g, vitamin B1 0.2mg, vitamin B6 0.1mg, vitamin B12
0.1ug, potassium chloride 0.3g, zinc gluconate 12ug, sodium citrate 0.2g, citric acid 0.4g, malic acid 5mg, ginseng 25mg,
Remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 3
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 12g, oligofructose 10g, vitamin B1 0.3mg, vitamin B6 0.1mg, vitamin B12
0.2ug, potassium chloride 0.6g, zinc gluconate 10ug, sodium citrate 0.3g, 0.2 g of citric acid, malic acid 20mg, ganoderma lucidum 32mg,
Remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 4
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 14g, oligofructose 35g, vitamin B1 0.2mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.5g, zinc gluconate 12ug, sodium citrate 0.3g, 0.1 g of citric acid, malic acid 30mg, Schisandra chinensis
28mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 5
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 12.5g, oligofructose 20g, vitamin B1 0.2mg, vitamin B6 0.1mg, vitamin B12
0.1ug, potassium chloride 0.3g, zinc gluconate 10ug, sodium citrate 0.1g, citric acid 0.2g, malic acid 23mg, Morinda officinalis
36mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 6
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 12g, oligofructose 15g, vitamin B1 0.22mg, vitamin B6 0.17mg, vitamin B12
0.12ug, potassium chloride 0.3g, zinc gluconate 10ug, sodium citrate 0.1g, citric acid 0.4g, malic acid 10mg, rhizoma polygonati
20mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 7
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 14g, oligofructose 3g, vitamin B1 0.2mg, vitamin B6 0.2mg, vitamin B12
0.1ug, potassium chloride 0.3g, zinc gluconate 10ug, sodium citrate 0.1g, citric acid 0.2g, malic acid 15mg, taurine
40mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 8
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 36g, vitamin B1 0.25mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.7g, zinc gluconate 11ug, sodium citrate 0.4g, 0.2 g of citric acid, malic acid 18mg, taurine
30mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 9
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 36g, vitamin B1 0.25mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.4g, zinc gluconate 11ug, sodium citrate 0.4g, 0.2 g of citric acid, malic acid 18mg, taurine
30mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 10
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 36g, vitamin B1 0.25mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.5g, zinc gluconate 11ug, sodium citrate 0.4g, 0.2 g of citric acid, malic acid 18mg, taurine
30mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 11
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 36g, vitamin B1 0.25mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.6g, zinc gluconate 11ug, sodium citrate 0.4g, 0.2 g of citric acid, malic acid 18mg, taurine
30mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Embodiment 12
A kind of ERAS energy drink, every 100ml beverage each material composition following by weight:
Maltodextrin 13g, oligofructose 36g, vitamin B1 0.25mg, vitamin B6 0.2mg, vitamin B12
0.2ug, potassium chloride 0.2g, zinc gluconate 11ug, sodium citrate 0.4g, 0.2 g of citric acid, malic acid 18mg, taurine
30mg, remaining is water.
The preparation method is the same as that of Example 1 for beverage described in the present embodiment.
Comparative example 1
Compared with Example 1, potassium chloride is not included in formula.
Experimental example 1
Selection carries out the patient 60 (preoperative row mechanicalness INTESTINAL CLEANSING) of laparoscopic surgery for colorectal neoplasm, is randomly divided into three
Group: A group, B group and C group.A group patient plays different fasting by tradition 00:00；B group patient 00:00 different fasting is to preoperative 2~3
Hour, it gives energy drink provided by comparative example 1 and takes orally, oral solution scale of construction 5ml/kg；C group patient 00:00 prohibits drink to preoperative 2
It~3 hours, gives energy drink provided by embodiment 1 and takes orally, oral rehydration amount 5ml/kg is oral.It is preoperative to record three groups of patients
And basic document, induced forestomach sinus portion ultrasound data, perioperative blood potassium data, gastrointestinal function recovery data etc. refer in art
Mark, concrete outcome is as shown in table 1~3.
Data and antrum portion ultrasonic examination data before 1 each group patient of table induces
Note: ※ B group vs.A group, value < 0.05 P；§ C group vs.A group, value < 0.05 P；Thirsty (starvation/anxiety) scoring: 0 point
Represent that patient is thirsty not at all (starvation/anxiety), 10 points represent patient it is contemplated that most thirsty (starvation/anxiety) feeling；Mouthful
Sense scoring: 0 point to represent mouthfeel excessively poor, and 10 points to represent mouthfeel very good.
2 each group patient's hypopotassaemia incidence of table and severity
Note: ※ B group vs.A group, value < 0.05 P；§ C group vs.A group, value < 0.05 P；
3 each group patient's gastrointestinal function recovery situation of table and related complication
Note: § C group vs.A group, value < 0.05 P；
As shown in table 1~3 statistics indicate that: three groups of basic document no difference of science of statistics.
As can be seen from the data in table 1, B group and the preceding thirsty scoring of C group induction are substantially less than A group (P < 0.001), B group and C group
Hungry scoring is substantially less than A group (P < 0.001) before induction, and it is bad that preoperative oral rehydration can be thirsty with reduction of patient, hungry etc.
Impression.Three groups of patient's antrum portion's areas and estimation intragastric volume and antrum ultrasound are classified equal no difference of science of statistics, preoperative 2~3h
Oral rehydration 5ml/kg does not increase induced forestomach internal volume, and tri- groups of A, B, C preoperative hypopotassaemia incidences be respectively 85%,
80%, the incidence of 30%, C group is substantially less than A group and B group (P < 0.05), this orally kalium supplement scheme can substantially reduce preoperative
The generation of hypopotassaemia.
From the data in table 2, it can be seen that occur in 17 patients of hypopotassaemia in A group, 10 patients are slight hypopotassaemia, 5
For the low potassium of moderate, 2 low potassium of generation severe, and in 6 hypopotassaemia patients of C group, 5 patients are slight hypopotassaemia, 1
For the low potassium of moderate, there is the low potassium of severe in no patient.Also there is significant difference between the ratio and A group of the different low potassium degree of C group
(P < 0.001), this orally kalium supplement scheme also reduce the degree of low potassium other than reducing the incidence of preoperative hypopotassaemia.
Meanwhile by the analysis of the data of table 3 it is found that the time of out-of-bed activity for the first time of C group patient, for the first time evacuation time, for the first time
The incidence of defecation time, for the first time eating time and postoperative abdominal distention is below A, B group patient (P < 0.05).
Conclusion: preoperative oral rehydration can be relieved the preoperative bad impression such as thirsty, hungry of patient, not increase the super lower antrum of B
Portion's area and intragastric volume.Preoperative orally kalium supplement can reduce preoperative hypopotassaemia incidence and mitigate low potassium severity, and
Accelerate gastrointestinal function recovery.
Experimental example 2
Energy drink provided by embodiment 1~12 is placed 12 months at room temperature, its stability is observed, surveys simultaneously
Its fixed pH value.
The effect of in order to further verify this energy drink, select the guidance of ERAS theory it is lower carry out ear-nose-throat department, gynaecology,
The patient of hepatobiliary surgery totally 260 (preoperative non-row mechanicalness INTESTINAL CLEANSING), is randomly divided into 13 groups.Allow every group respectively
Patient 00:00 prohibits drink to preoperative 2~3 hours, gives energy drink provided by embodiment 1~12 and comparative example 1 and takes orally, takes orally
Amount infused 5ml/kg is oral.Patient is recorded to the scoring of energy drink and the blood potassium data of perioperative.
Specific test result is as shown in table 4.
Table 4
From the data in table 4, it can be seen that energy drink provided by embodiment 1~12 is stablized, easily stored and easy, quick,
Safely reach and mend potassium effect, and is in good taste, is not in that patient is allowed to generate the adverse reactions such as Nausea and vomiting, abdominal distension, abdominal pain.
The above embodiment is merely an example for clearly illustrating the present invention, and is not to implementation of the invention
The restriction of mode.For those of ordinary skill in the art, can also make on the basis of the above description it is other not
With the variation or variation of form.There is no necessity and possibility to exhaust all the enbodiments.It is all in spirit of the invention and
Made any modifications, equivalent replacements, and improvements etc. within principle, should be included in the claims in the present invention protection scope it
It is interior.
Claims (10)
1. a kind of ERAS energy drink, which is characterized in that be made of following raw material: maltodextrin, oligofructose, vitamin B1,
Vitamin B6, vitamin B12, potassium chloride, zinc gluconate, sodium citrate, citric acid, malic acid, taurine, water.
2. ERAS energy drink according to claim 2, which is characterized in that the weight of potassium chloride in every 100ml beverage
For 0.2 ~ 0.7 g.
3. ERAS energy drink according to claim 1 or 2, which is characterized in that every 100 ml beverage is by weight following
Each material composition:
12 ~ 14 g of maltodextrin, 3 ~ 50 g of oligofructose, 0.2 ~ 0.3mg of vitamin B1,0.1 ~ 0.2 mg of vitamin B6,
0.1 ~ 0.2 ug of vitamin B12,0.3 ~ 0.6 g of potassium chloride, 10 ~ 12 ug of zinc gluconate, 0.1 ~ 0.4 g of sodium citrate,
0.1 ~ 0.4 g of citric acid, 1 ~ 30 mg of malic acid, 20 ~ 50 mg of taurine,
Remaining is water.
4. ERAS energy drink according to claim 3, which is characterized in that the weight of potassium chloride in every 100ml beverage
For 0.4 ~ 0.5 g.
5. ERAS energy drink according to claim 1, which is characterized in that the beverage at 25 DEG C, viscosity is 1.3 ~
1.8 mpa·s。
6. described in any item ERAS energy drinks according to claim 1 ~ 4, which is characterized in that the maltodextrin is M200
Type.
7. ERAS energy drink according to claim 1, which is characterized in that the pH value of the energy drink is 4.0 ~ 5.0.
8. described in any item ERAS energy drinks according to claim 1 ~ 6, which is characterized in that the taurine is by ginseng, five
One or more of taste, rhizoma polygonati, ganoderma lucidum, Morinda officinalis substitution.
9. the preparation method of described in any item ERAS energy drinks according to claim 1 ~ 6, which is characterized in that including walking as follows
It is rapid:
(1) maltodextrin and a certain amount of water are weighed, maltodextrin is completely dissolved under the action of ultrasound after mixing, obtains malt
Dextrin in aqueous solution；
(2) sodium citrate and a certain amount of water are weighed, 40 ~ 50 DEG C of stirrings is heated to being completely dissolved, is cooled to room temperature to obtain lemon
Acid sodium aqueous solution；
(3) the maltodextrin aqueous solution made from step (1) is poured into material-compound tank A, lower addition step is then stirred at room temperature
(2) sodium citrate aqueous solution made from obtains solution A；
(4) oligofructose, vitamin B1, vitamin B6, vitamin B12, zinc gluconate, taurine, citric acid, apple are weighed
Acid, potassium chloride are added in material-compound tank B, and a certain amount of water are added, and are then heated to 40 ~ 50 DEG C of stirrings to after being completely dissolved, cold
But to room temperature, solution B is obtained；
(5) water constant volume is used after mixing solution A and B.
10. the preparation method of ERAS energy drink according to claim 9, which is characterized in that ultrasound described in step (1)
Wave frequency rate is 20 ~ 80KHz.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811245988.2A CN109497376A (en) | 2018-10-24 | 2018-10-24 | A kind of ERAS energy drink and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811245988.2A CN109497376A (en) | 2018-10-24 | 2018-10-24 | A kind of ERAS energy drink and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109497376A true CN109497376A (en) | 2019-03-22 |
Family
ID=65746869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811245988.2A Pending CN109497376A (en) | 2018-10-24 | 2018-10-24 | A kind of ERAS energy drink and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109497376A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771762A (en) * | 2019-11-08 | 2020-02-11 | 黑河市第一人民医院 | Functional beverage suitable for diabetic patients and capable of resisting stress reaction before and after operation |
| CN111406935A (en) * | 2020-05-27 | 2020-07-14 | 山东探克生物科技股份有限公司 | Carbohydrate component formula food suitable for preoperative taking and having special medical application and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105167074A (en) * | 2015-08-11 | 2015-12-23 | 宜昌人福药业有限责任公司 | Beverage for eliminating hunger sensation and bad mood and preparation method thereof |
| CN105795481A (en) * | 2016-03-24 | 2016-07-27 | 广州军区广州总医院 | Special nutritional supplement agent for preoperative patients |
| CN105942534A (en) * | 2016-07-01 | 2016-09-21 | 四川省洛源食品有限公司 | Vitamin sports functional beverage and making method thereof |
| CN106261360A (en) * | 2016-08-04 | 2017-01-04 | 深圳前海大健康家医疗管理有限公司 | A kind of compound maltodextrin fructose beverage and preparation method thereof and application thereof |
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN108142951A (en) * | 2018-01-31 | 2018-06-12 | 广州纽健生物科技有限公司 | Improve nutraceutical of postoperative insulin resistance and its preparation method and application |
-
2018
- 2018-10-24 CN CN201811245988.2A patent/CN109497376A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105167074A (en) * | 2015-08-11 | 2015-12-23 | 宜昌人福药业有限责任公司 | Beverage for eliminating hunger sensation and bad mood and preparation method thereof |
| CN105795481A (en) * | 2016-03-24 | 2016-07-27 | 广州军区广州总医院 | Special nutritional supplement agent for preoperative patients |
| CN105942534A (en) * | 2016-07-01 | 2016-09-21 | 四川省洛源食品有限公司 | Vitamin sports functional beverage and making method thereof |
| CN106261360A (en) * | 2016-08-04 | 2017-01-04 | 深圳前海大健康家医疗管理有限公司 | A kind of compound maltodextrin fructose beverage and preparation method thereof and application thereof |
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN108142951A (en) * | 2018-01-31 | 2018-06-12 | 广州纽健生物科技有限公司 | Improve nutraceutical of postoperative insulin resistance and its preparation method and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771762A (en) * | 2019-11-08 | 2020-02-11 | 黑河市第一人民医院 | Functional beverage suitable for diabetic patients and capable of resisting stress reaction before and after operation |
| CN111406935A (en) * | 2020-05-27 | 2020-07-14 | 山东探克生物科技股份有限公司 | Carbohydrate component formula food suitable for preoperative taking and having special medical application and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101015381A (en) | Drink for dispelling effects of liquor and protecting liver and its preparation method | |
| Holmes et al. | Dysphagia in severe anorexia nervosa and potential therapeutic intervention: a case series | |
| CN109497376A (en) | A kind of ERAS energy drink and preparation method thereof | |
| JPH0678235B2 (en) | Gastrointestinal mucosal tissue disorder therapeutic agent | |
| Caterson | Medical management of obesity and its complications | |
| CN107927515A (en) | For preoperative and postoperative solid beverage and drink | |
| CN104643190A (en) | Liver-protection health drink | |
| JP2008266291A (en) | Food and drink and medicine composition for oral administration for improving aciduria that have fucoidan as active ingredient | |
| JP5527986B2 (en) | Pharmaceutical composition | |
| KR101122703B1 (en) | Composition for improving and preventing snoring | |
| JP2015514790A (en) | How to improve swallowing efficiency | |
| CN103845526A (en) | Traditional Chinese medicine tea drink for treating hypertension associated with diabetes | |
| CN110947008A (en) | Orally-taken oxybuprocaine hydrochloride gastroscope lubricating liquid and preparation method thereof | |
| CN110037221A (en) | A kind of Dealcoholic solid beverage and preparation method thereof | |
| CN103948591B (en) | A kind of slimming agents | |
| JP6533784B2 (en) | Eye fatigue improver | |
| CN103740564B (en) | Antifatigue prolonging life and preserving health wine and preparation method thereof | |
| WO2017102965A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
| JP7398192B2 (en) | Antistress composition | |
| Laddie et al. | Gastrointestinal and liver-related symptoms in paediatric palliative care | |
| Hutchison | The elements of medical treatment | |
| RU2361599C1 (en) | Pharmaceutical composition possessing sedative and anxyolitic action | |
| CN101959522A (en) | Ketone accumulation inhibitor | |
| Rizvi | The ammonium chloride treatment of schizophrenia | |
| CN115397262A (en) | Sleep quality improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |
|
| RJ01 | Rejection of invention patent application after publication |